Zimbabwe Pharmaceuticals and Healthcare Report Q2 2010

Executive Summary ....................................................5
SWOT Analysis............................................................6
Zimbabwe Pharmaceuticals And Healthcare Industry SWOT........................................... 6
Zimbabwe Political SWOT................................................................................................ 7
Zimbabwe Economic SWOT.............................................................................................. 8
Zimbabwe Business Environment SWOT .......................................................................... 9
Pharmaceutical Business Environment Ratings ........................................................................................10
Table: Middle East and Africa Pharmaceutical Business Environment Ratings,Q210 ........................................................................................ 10
Limits of Potential Returns ............................................................................................. 10
Risks to Realisation of Returns ....................................................................................... 11
Zimbabwe – Market Summary...................................13
Regulatory Regime....................................................14
Intellectual Property Developments................................................................................ 14
Pricing and Reimbursement Issues ................................................................................. 15
Public Drug Procurement............................................................................................... 15
Industry Developments.............................................17
Epidemiology.............................. 17
Communicable Diseases ................................................................................................. 18
Cholera Crisis............................. 18
HIV/AIDS Situation..................... 20
Healthcare System ...................... 21
Healthcare Funding.................... 23
Recent Healthcare System Developments ....................................................................... 25
Health Insurance ........................ 26
Healthcare Staff .......................... 27
Pharmaceutical Sector................ 28
Recent Pharmaceutical Sector Developments................................................................. 30
Table: ARV Prices Available Through Direct Purchase From Roche (CHF) .................. 34
Pharmacy Sector......................... 34
Traditional Medicine .................. 35
Biotechnology Sector Developments ............................................................................... 35
Medical Devices.......................... 36
Industry Forecast Scenario......................................37
Overall Market Forecasts ............................................................................................... 37
Key Growth Factors – Industry....................................................................................... 39
Key Growth Factors – Macroeconomic .......................................................................... 41
Table: Zimbabwe – Economic Activity............................................................................ 43
Prescription Drug Market Forecast................................................................................ 44
Patented Drug Market Forecast ..................................................................................... 46
Generic Drug Market Forecast....................................................................................... 47
OTC Medicine Market Forecast ..................................................................................... 48
Pharmaceutical Trade Forecasts .................................................................................... 49
Other Healthcare Data Forecasts................................................................................... 51
Key Risks to Forecasts ............................................................................................ 52
Competitive Landscape............................................53
Company Profiles......................................................54
Indigenous Companies..................... 54
Datlabs ....................................... 54
Varichem Laboratories ............... 56
CAPS Holdings ........................... 58
Multinational Companies................. 60
Ranbaxy ...................................... 60
Pfizer .......................................... 62
Country Snapshot: Zimbabwe Demographic Data .....................................................................................64
Section 1: Population.................. 64
Table: Demographic Indicators, 2005-2030................................................................... 64
Table: Rural/Urban Breakdown, 2005-2030 .................................................................. 65
Section 2: Education and Healthcare ............................................................................. 65
Table: Education, 2000-2003 ......................................................................................... 65
Table: Vital Statistics, 2005-2030................................................................................... 65
Section 3: Labour Market and Spending Power.............................................................. 66
Table: Employment Indicators, 1997 And 1999*............................................................ 66
Table: Average Annual Manufacturing Wages, 1996-2002 ............................................ 66
Forecast Modelling ............................................67
How We Generate Our Pharmaceutical Industry Forecasts ................................................ 67
Pharmaceutical Business Environment Ratings Methodology ............................................. 68
Ratings Overview........................ 68
Table: Pharmaceutical Business Environment Indicators .............................................. 69
Weighting.................................... 70
Table: Weighting Of Components ................................................................................... 70
Sources ............................................ 70
Forecast Tables .........................................................71